A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Greenville, South Carolina 29605, United States
East Seattle, Washington 98109, United States
Novo Hamburgo, Rio Grande do Sul 93510-250, Brazil
Porto Alegre, São Paulo 90110-270, Brazil
Santo André, São Paulo 09060-650, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
São Paulo, São Paulo 01246-000, Brazil
Esslingen A. N., Baden-Wurttemberg 73730, Germany
Mainz, Rhineland-Palatinate 55131, Germany
Cremona, 26100, Italy
Kita-gun, Kagawa-ken 761-0793, Japan
Yufu-shi, Oita Prefecture 879-5593, Japan
Izumi-shi, Osaka 594-0071, Japan
Hidaka-shi, Saitama 350-1298, Japan
Kitaadachi-gun, Saitama 362-0806, Japan
Comuna Floresti, Cluj 407280, Romania
Saint Petersburg, Leningrado 197758, Russia
Hwasun-gun, Jeollanam-do 58128, South Korea
Patumwan, Bangkok 10330, Thailand
Muang, Chiang Mai 50200, Thailand